In a recent phase I study, CR, CR + CRi, and ORR were observed, respectively, in 21.6%, 30.4%, and 41.6% of patients with IDH1-mutated AML receiving ivosidenib 500-mg monotherapy, with a median duration of 8.2 months, 9.3 months, and 6.5 months [78]. The gene discussed is IDH1; the disease is acute myeloid leukemia.